Showing results (2151-2160 of 2,629) with videos related to

Sort By:
Pageof 263
JCO Precision Oncology|May 6, 2026
NTRK Gene Fusions: A Compendium of Fusion Partners and Tumor TypesSoo-Ryum Yang, Matteo Repetto, Erin R Rudzinski, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 30, 2018
Long-term immunogenicity and immune persistence of live attenuated and inactivated hepatitis a vaccines: a report on additional observations from a phase IV studyJ Luo, X Wang, F Ma, et al.
The Journal of Clinical Investigation|September 10, 2019
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcomaIan Bayles, Malgorzata Krajewska, W Dean Pontius, et al.
British Journal of Cancer|February 18, 2011
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activityK-p Kim, G Jang, Y S Hong, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|December 6, 2018
The temporal pattern of immune and inflammatory proteins prior to a recurrent coronary event in post-acute coronary syndrome patientsMaxime M Vroegindewey, Rohit M Oemrawsingh, Isabella Kardys, et al.
Cell Reports|September 14, 2025
Connexin 43 drives glioblastoma cancer stem cell phenotypes through a WNK lysine-deficient protein kinase 1-c-MYC signaling axisErin E Mulkearns-Hubert, Nicole Hajdari, Ellen S Hong, et al.
Targeted Oncology|September 24, 2021
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic CancerKathleen N Moore, David S Hong, Manish R Patel, et al.
Oncotarget|December 19, 2012
PIK3CA mutations in advanced cancers: characteristics and outcomesFilip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology|January 18, 2014
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancersJennifer J Wheler, Filip Janku, Gerald S Falchook, et al.
Archives of Dermatological Research|April 22, 2016
Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitorsG S Falchook, P Rady, J C Konopinski, et al.
Pageof 263